New Release: Alpha testing version has been released.

Triamcinolone Acetonide

H02A - Corticosteroids for systemic use, plain ATC H02AB08 Small molecule approved 1960 Parenteral Topical

JFDA label: Panbicort 40mg Inj.

Mechanism of Action

Agonist of Glucocorticoid receptor — Glucocorticoid receptor agonist

TargetActionGene / class
Glucocorticoid receptor efficacy AGONIST NR3C1

Indications

Approved

  • Anemia — anemia
  • Arthritis, Gouty — gout
  • Arthritis, Rheumatoid — rheumatoid arthritis
  • Asthma — asthma
  • Bursitis — frozen shoulder
  • Dermatitis — dermatitis
  • Multiple Sclerosis — multiple sclerosis
  • Mycoses — fungal infectious disease
  • Nasal Obstruction — Nasal congestion
  • Osteoarthritis — osteoarthritis
  • Pain — pain
  • Rhinitis, Allergic, Seasonal — seasonal allergic rhinitis
  • Serum Sickness — type III hypersensitivity reaction disease
  • Skin Diseases — skin disease
  • Tennis Elbow — lateral epicondylitis
  • Tenosynovitis — tenosynovitis
  • Tuberculosis, Pulmonary — pulmonary tuberculosis
  • Wounds and Injuries — injury

Off-label

  • Alopecia Areata
  • Breast Neoplasms
  • Cataract
  • Chalazion
  • Choroidal Neovascularization
  • Complex Regional Pain Syndromes
  • Cough
  • Cystitis, Interstitial
  • Dermatitis, Atopic
  • Diabetic Retinopathy
  • Dupuytren Contracture
  • Eye Injuries
  • Glaucoma
  • Hand Dermatoses
  • Humeral Fractures
  • Keloid
  • Lichen Planus
  • Lichen Planus, Oral
  • Macular Degeneration
  • Macular Edema
  • Optic Neuropathy, Ischemic
  • Osteoarthritis, Hip
  • Osteoarthritis, Knee
  • Otitis Media with Effusion
  • Pemphigoid, Benign Mucous Membrane
  • Pemphigus
  • Psoriasis
  • Radiculopathy
  • Retinal Vein Occlusion
  • Rhinitis
  • Shoulder Pain
  • Tendinopathy
  • Ulnar Neuropathies
  • Uveal Melanoma
  • Uveitis
  • Uveomeningoencephalitic Syndrome
  • Vitiligo
  • Vitreoretinopathy, Proliferative
  • Wet Macular Degeneration

Contraindications

Source: openFDA

  • Triamcinolone acetonide injectable suspension is contraindicated in patients who are hypersensitive to any components of this product (see WARNINGS: General ). Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Nervous system disorders (3)

Very Common Headache

Rare Dizziness · Glaucoma

Immune system disorders (2)

Rare Anaphylactic shock · Hypersensitivity

Endocrine disorders (1)

Rare Blood cortisol decreased

Gastrointestinal disorders (3)

Common Diarrhoea · Dyspepsia

Rare Nausea

Skin and subcutaneous tissue disorders (3)

Common Dermatitis · Rash

Rare Pruritus

Musculoskeletal and connective tissue disorders (1)

Common Back pain

Psychiatric disorders (1)

Rare Insomnia

Infections and infestations (7)

Very Common Pharyngitis · Rhinitis

Common Bronchitis · Infection · Influenza · Nasopharyngitis · Sinusitis

Investigations (1)

Common Body temperature increased

General disorders and administration site conditions (10)

Very Common Sneezing

Common Excoriation · Pain · Tooth disorder

Uncommon Oropharyngeal discomfort · Oropharyngeal pain · Sinus congestion

Rare Asthenia · Cataract · Fatigue

Respiratory, thoracic and mediastinal disorders (7)

Very Common Epistaxis

Common Asthma · Cough · Laryngeal pain · Nasal discomfort · Rhinorrhoea

Rare Dyspnoea

Dosing

Source: openFDA

General NOTE: CONTAINS BENZYL ALCOHOL (see PRECAUTIONS). The initial dose of triamcinolone acetonide injectable suspension may vary from 2.5 mg to 100 mg per day depending on the specific disease entity being treated (see Dosage section below). However, in certain overwhelming, acute, life-threatening situations, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Dosage SYSTEMIC The suggested initial dose is 60 mg, injected deeply into the gluteal muscle . Atrophy of subcutaneous fat may occur if the injection is not properly given. Dosage is usually adjusted within the range of 40 mg to 80 mg, depending upon patient response and duration of relief. However, some patients may be well controlled on doses as low as 20 mg or less. Hay fever or pollen asthma: Patients with hay fever or pollen asthma who are not responding to pollen administration and other conventional therapy may obtain a remission of symptoms lasting throughout the pollen season after a single injection of 40 mg to 100 mg. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 160 mg of triamcinolone for a week followed by 64 mg every other day for one month are recommended (see PRECAUTIONS: Neuro-Psychiatric ). In pediatric patients, the initial dose of triamcinolone may vary depending on the specific disease entity being treated. The range of initial doses is 0.11 mg/kg/day to 1.6 mg/kg/day in 3 or 4 divided doses (3.2 mg/m 2 bsa/day to 48 mg/m 2 bsa/day). For the purpose of comparison, the following is the equivalent milligram dosage of the various glucocorticoids: Cortisone, 25 Triamcinolone, 4 Hydrocortisone, 20 Paramethasone, 2 Prednisolone, 5 Betamethasone, 0.75 Prednisone, 5 Dexamethasone, 0.75 Methylprednisolone, 4 These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered. LOCAL Intra-articular administration: A single local injection of triamcinolone acetonide is frequently sufficient, but several injections may be needed for adequate relief of symptoms. Initial dose: 2.5 mg to 5 mg for smaller joints and from 5 mg to 15 mg for larger joints, depending on the specific disease entity being treated. For adults, doses up to 10 mg for smaller areas and up to 40 mg for larger areas have usually been sufficient. Single injections into several joints, up to a total of 80 mg, have been given. Administration GENERAL STRICT ASEPTIC TECHNIQUE IS MANDATORY. The vial should be shaken before use to ensure a uniform suspension. Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration). Agglomeration occurs when the drug substance separates from the solution and appears as a white precipitate in the vial. An agglomerated product should be discarded and sho

Warnings & Precautions

Source: openFDA

Warnings & Precautions

Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids (see WARNINGS: Neurologic ). Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. General Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see PRECAUTIONS: Pediatric Use ). Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS ). Cases of serious anaphylaxis, including death, have been reported in individuals receiving triamcinolone acetonide injection, regardless of the route of administration. Because triamcinolone acetonide injectable suspension is suspension, it should not be administered intravenously. Unless a deep intramuscular injection is given, local atrophy is likely to occur. (For recommendations on injection techniques, see DOSAGE AND ADMINISTRATION .) Due to the significantly higher incidence of local atrophy when the material is injected into the deltoid area, this injection site should be avoided in favor of the gluteal area. Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation. Tri

Chemistry & Properties

2D structure
FormulaC24H31FO6
Molecular weight434.5 g/mol
IUPAC name(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
CAS76-25-5
PubChem CID6436
InChIKeyYNDXUCZADRHECN-JNQJZLCISA-N
logP2.42 (XLogP 2.5)
Polar surface area93.06 Ų
H-bond acceptors / donors6 / 2
Drug-likeness (QED)0.69
Lipinski violations0
SMILESCC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrantYes

Enzyme interactions

EnzymeRoleDetail
CYP2C8Inhibitor
CYP3A4Substrate

Receptor binding (top 1)

TargetActionAffinity
Glucocorticoid receptor (NR3C1) Agonist pIC50 8.2

Transporters

BCRP (Inhibitor)BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (6)

BrandForm / strengthPackAgentCitizen (JOD)
Panderm Cream Cream 10.000000 IU/100 g, 0.025 g/100 g, 0.25 g/100 g, 0.1 g/100 g 15 g tube pack varies Professional Drug Store 1.420
Kenaphil Cream Cream 0.326 g/tube, 0.00375 g/tube, 0.055161 g/tube, 0.015 g/tube 15 g tube PHILADELPHIA PHAEMACEUTICALS.COMP/JORDAN 1.510
Ecorex Plus Cream Cream 1 %, 0.1 % 15 g tube pack varies Hayat Pharmaceutical Industries CO.PLC/JORDAN 1.690
Panderm Cream Cream 10.000000 IU/100 g, 0.025 g/100 g, 0.25 g/100 g, 0.1 g/100 g 30 g tube pack varies Professional Drug Store 2.480
Ecorex Plus Cream Cream 1 %, 0.1 % 30 g tube pack varies Hayat Pharmaceutical Industries CO.PLC/JORDAN 3.210
Panbicort 40mg Inj. Injection 40 mg/ml 1 ml AL Rahma Drug Store 14.680